endogenous opioid peptides
Recently Published Documents


TOTAL DOCUMENTS

276
(FIVE YEARS 12)

H-INDEX

40
(FIVE YEARS 2)

Author(s):  
Shamseddin Ahmadi ◽  
Kayvan Masoudi ◽  
Shiva Mohammadi Talvar ◽  
Mohammad Zobeiri ◽  
Amir Khanizad ◽  
...  

Backgrounds: Molecular mechanisms involved in adverse effects of morphine, including tolerance and dependence, have remained elusive. We examined possible alterations in the gene expression of proenkephalin (Penk), prodynorphin (Pdyn), and mu-opioid receptor (Oprm1) in reward brain areas following frequent morphine treatment. Methods: Two groups of male Wistar rats were used. The groups received either saline (1 mL/kg) or morphine (10 mg/kg) twice daily for eight days. On day 8, rats were decapitated, brain areas involved in addiction were dissected, including the midbrain, striatum, prefrontal cortex (PFC), hippocampus, and hypothalamus, and gene expression was evaluated with real-time PCR. Results: Prolonged morphine treatment decreased Penk, Pdyn, and Oprm1 gene expressions in the midbrain but upregulated them in the striatum compared to the control group treated with saline. Significant increases in Pdyn and Oprm1 gene expressions were detected in the PFC, but there was no significant difference in Penk gene expression between the two groups. Besides, Pdyn gene expression was decreased in the hippocampus and hypothalamus; however, no significant differences in Penk and Oprm1 gene expressions were detected between the groups in these areas. Conclusions: The expression of endogenous opioid peptides and receptors after frequent use of morphine follows a region specificity in brain areas involved in addiction. These alterations may result in new physiological setpoints outside the normal range, which need to be considered when using morphine in medicine.


Author(s):  
José M. Hernández-Hernández ◽  
Jaime Gallegos-Sánchez ◽  
Carlos M. Becerril-Pérez ◽  
Arturo Pro-Martínez ◽  
Ponciano Pérez-Hernández

Objective: To describe the management strategies of controlled suckling and the male effect to reduce postpartum anestrus, and to show the participation of kisspeptin to regulate the effect of both factors. Design/Methodology/Approach: A review of scientific publications was conducted, in order to show the importance of suckling and the male effect as strategies to reduce postpartum anestrus in the ewe, as well as the relation of kisspeptin with both factors. Results: Seasonal anestrus can be avoided with the use of breeds adapted to the local environment, such as Pelibuey. Postpartum anestrus occurs mainly as a result of suckling, since the latter inhibits the pulsating secretion of the gonadotropin-releasing hormone (GnRH) and the luteinizing hormone (LH). The exact path of this inhibition is unknown, although it seems that endogenous opioid peptides and kisspeptin are intermediaries. Controlled suckling and the male effect are management strategies that improve the reproductive behavior of postpartum ewes. Kisspeptin regulates the influence of the male effect through the secretion of GnRH/LH. Study Limitations/Implications: To understand the impacts of suckling and the male effect on the duration of postpartum anestrus, as well as the participation of kisspeptin in the regulation of both effects, will allow designing management strategies to improve the reproductive efficiency of the ewes. Findings/Conclusions: Controlled suckling and the male effect reduce postpartum anestrus and improve the reproductive behavior of the ewes; advancing knowledge of the kisspeptin effect could improve the effectiveness of both techniques.


2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Sha-sha Ding ◽  
Yuan Xu ◽  
Ying-ying Zhang ◽  
Jing-zi Chen ◽  
Shou-hai Hong

Increasing evidences demonstrate that acupuncture is effective in treating inflammatory pain. Recent studies have found that peripheral endogenous opioid peptides in the area of inflammation are involved in acupuncture-treating inflammatory pain. However, the source of endogenous opioid peptides in local area of inflammation and the mechanism of acupuncture regulating these opioid peptides remain unclear. Studies have demonstrated that neutrophils infiltrated in the inflamed tissue contain and release opioid peptides. Chemokine (C-X-C motif) ligand 1 (CXCL1) is one of the key neutrophil chemokines and can promote the blood neutrophil recruitment to the area of inflammation. In our previous experiments, we found that acupuncture could alleviate inflammatory pain and significantly increase the concentration of chemokine CXCL1 in the blood of rats with inflammatory pain. So we suppose that increased concentration of CXCL1 by acupuncture could activate the blood opioid-containing neutrophils via its main receptor chemokine receptor type 2 (CXCR2) and promote them recruit to the inflamed tissue to release opioid peptides, participating in the analgesic effect of acupuncture.


2021 ◽  
Vol 118 (16) ◽  
pp. e2000017118
Author(s):  
Ram Kandasamy ◽  
Todd M. Hillhouse ◽  
Kathryn E. Livingston ◽  
Kelsey E. Kochan ◽  
Claire Meurice ◽  
...  

Positive allosteric modulators (PAMs) of the mu-opioid receptor (MOR) have been hypothesized as potentially safer analgesics than traditional opioid drugs. This is based on the idea that PAMs will promote the action of endogenous opioid peptides while preserving their temporal and spatial release patterns and so have an improved therapeutic index. However, this hypothesis has never been tested. Here, we show that a mu-PAM, BMS-986122, enhances the ability of the endogenous opioid Methionine-enkephalin (Met-Enk) to stimulate G protein activity in mouse brain homogenates without activity on its own and to enhance G protein activation to a greater extent than β-arrestin recruitment in Chinese hamster ovary (CHO) cells expressing human mu-opioid receptors. Moreover, BMS-986122 increases the potency of Met-Enk to inhibit GABA release in the periaqueductal gray, an important site for antinociception. We describe in vivo experiments demonstrating that the mu-PAM produces antinociception in mouse models of acute noxious heat pain as well as inflammatory pain. These effects are blocked by MOR antagonists and are consistent with the hypothesis that in vivo mu-PAMs enhance the activity of endogenous opioid peptides. Because BMS-986122 does not bind to the orthosteric site and has no inherent agonist action at endogenously expressed levels of MOR, it produces a reduced level of morphine-like side effects of constipation, reward as measured by conditioned place preference, and respiratory depression. These data provide a rationale for the further exploration of the action and safety of mu-PAMs as an innovative approach to pain management.


2021 ◽  
Vol 22 (7) ◽  
pp. 3779
Author(s):  
Anna Abrimian ◽  
Tamar Kraft ◽  
Ying-Xian Pan

There exist three main types of endogenous opioid peptides, enkephalins, dynorphins and β-endorphin, all of which are derived from their precursors. These endogenous opioid peptides act through opioid receptors, including mu opioid receptor (MOR), delta opioid receptor (DOR) and kappa opioid receptor (KOR), and play important roles not only in analgesia, but also many other biological processes such as reward, stress response, feeding and emotion. The MOR gene, OPRM1, undergoes extensive alternative pre-mRNA splicing, generating multiple splice variants or isoforms. One type of these splice variants, the full-length 7 transmembrane (TM) Carboxyl (C)-terminal variants, has the same receptor structures but contains different intracellular C-terminal tails. The pharmacological functions of several endogenous opioid peptides through the mouse, rat and human OPRM1 7TM C-terminal variants have been considerably investigated together with various mu opioid ligands. The current review focuses on the studies of these endogenous opioid peptides and summarizes the results from early pharmacological studies, including receptor binding affinity and G protein activation, and recent studies of β-arrestin2 recruitment and biased signaling, aiming to provide new insights into the mechanisms and functions of endogenous opioid peptides, which are mediated through the OPRM1 7TM C-terminal splice variants.


Author(s):  
Achla Gupta ◽  
Srinivas Gullapalli ◽  
Hui Pan ◽  
Dinah L. Ramos-Ortolaza ◽  
Michael D. Hayward ◽  
...  

Author(s):  
Jennifer M. Kunselman ◽  
Achla Gupta ◽  
Ivone Gomes ◽  
Lakshmi A. Devi ◽  
Manoj A. Puthenveedu

AbstractMany signal transduction systems have an apparent redundancy built into them, where multiple physiological agonists activate the same receptors. Whether this is true redundancy, or whether this provides as-yet unrecognized specificity in downstream signaling, is not well understood. We address this question using the kappa opioid receptor (KOR), a physiologically relevant G protein-coupled receptor (GPCR) that is activated by multiple members of the Dynorphin family of opioid peptides. We show that, although highly related Dynorphins bind and activate KOR to similar extents on the cell surface, they localize KOR to distinct subcellular compartments, dictate different post-endocytic fates of the receptor, and differentially induce KOR signaling from the degradative pathway. Our results show that seemingly redundant endogenous opioid peptides that are often co-released can in fact fine-tune signaling by differentially regulating the subcellular spatial profile of GPCR localization and signaling.


Sign in / Sign up

Export Citation Format

Share Document